Zhang Fang, He Xu, Xiang Wei, Li Shu Chuen
a College of Business Administration , Shenyang Pharmaceutical University , Shenyang , Liaoning , PR China.
b Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences & Pharmacy , University of Newcastle , Callaghan , NSW , Australia.
J Med Econ. 2017 May;20(5):510-517. doi: 10.1080/13696998.2017.1280501. Epub 2017 Jan 27.
To evaluate the quality of Chinese pharmacoeconomic-evaluation literature published between 2012-2014 retrieved from the Chinese National Knowledge Infrastructure (CNKI) in order to assess their adherence to recommendations of the Chinese Pharmacoeconomic Guidelines.
Identified literature was screened according to pre-specified criteria to access legibility for inclusion. Each included piece of literature was systematically compared against the recommendations proposed by the relevant Chinese guidelines.
After culling, 259 studies were included in the comparative analysis. When compared to a previous study evaluating the quality of similar literature published between 1997-2007, the results showed improvements in certain technical aspects over the years. Particularly, an improvement was observed in more diverse evaluation methods being used, increased use of cost-utility analysis (2.43% in 2012-2014 vs 0.26% in 1997-2007) and use of discounting (45% in 2012-2014 vs 4.35% in 1997- 2007). In addition, a small number of studies were starting to apply modeling.
The quality of economic evaluation literature has improved in recent years, with more researchers realizing the importance and necessity of using discounting, sensitivity analysis, and modeling when conducting economic evaluation. This study also highlights certain important areas needing further attention when conducting economic evaluations in China. These include the ICER threshold of economic analysis, more detailed guidance in performing sensitivity analysis and modeling, as well as transferability of cost data across different regions. Overall, the results would support the positive contribution of the Chinese Economic Guideline in promoting economic evaluations in China.
评估从中国知网(CNKI)检索到的2012 - 2014年发表的中国药物经济学评价文献的质量,以评估其对《中国药物经济学指南》建议的遵循情况。
根据预先设定的标准筛选已识别的文献,以确定其纳入的可读性。将每篇纳入的文献与相关中国指南提出的建议进行系统比较。
剔除后,259项研究纳入比较分析。与之前一项评估1997 - 2007年发表的类似文献质量的研究相比,结果显示这些年在某些技术方面有所改进。特别是,观察到使用了更多样化的评价方法,成本效用分析的使用增加(2012 - 2014年为2.43%,1997 - 2007年为0.26%)以及贴现的使用(2012 - 2014年为45%,1997 - 2007年为4.35%)。此外,少数研究开始应用模型。
近年来经济评价文献的质量有所提高,越来越多的研究人员意识到在进行经济评价时使用贴现、敏感性分析和模型的重要性和必要性。本研究还强调了在中国进行经济评价时需要进一步关注的某些重要领域。这些领域包括经济分析的增量成本效果比阈值、进行敏感性分析和模型的更详细指导,以及不同地区成本数据的可转移性。总体而言,结果将支持《中国经济指南》对促进中国经济评价的积极贡献。